Literature DB >> 28666778

PSMA ligands in prostate cancer - Probe optimization and theranostic applications.

Susanne Lütje1, Roger Slavik2, Wolfgang Fendler3, Ken Herrmann4, Matthias Eiber5.   

Abstract

Due to its selective overexpression in prostate cancer (PCa), the prostate-specific membrane antigen (PSMA) has been recognized as a highly promising target for diagnostic and therapeutic applications. So far, various PSMA ligands have been developed for radiolabeling with radioisotopes such as 68Ga or 18F which can be used for specific visualization and diagnosis of PSMA-expressing PCa. In addition, PSMA ligands suitable for radiolabeling with 131I or 177Lu have become available to the clinics, allowing PSMA-based radioligand therapies. Here, we provide a comprehensive review of the most frequently used PSMA ligands, their structural modifications, and the impact of those on clinical applications.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Imaging; PSMA; Prostate cancer; Theranostics

Mesh：

Substances：

Year:  2017        PMID： 28666778     DOI： 10.1016/j.ymeth.2017.06.026

Source DB:  PubMed          Journal:  Methods        ISSN： 1046-2023            Impact factor:   3.608


  10 in total

1.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

Review 2.  Metamorphosis of prostate specific membrane antigen (PSMA) inhibitors.

Authors:  Zahra Nikfarjam; Farshid Zargari; Alireza Nowroozi; Omid Bavi
Journal:  Biophys Rev       Date:  2022-01-13

3.  Quantitative [Fe]MRI determination of the dynamics of PSMA-targeted SPIONs discriminates among prostate tumor xenografts based on their PSMA expression.

Authors:  Laurel O Sillerud
Journal:  J Magn Reson Imaging       Date:  2018-01-13       Impact factor: 4.813

Review 4.  Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Authors:  Rubel Chakravarty; Cerise M Siamof; Ashutosh Dash; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20

5.  Landscape Analysis of Phase 2 and 3 Clinical Trials for Targeted Radionuclide Therapy.

Authors:  Erik Mittra; Lisa Bodei
Journal:  J Nucl Med       Date:  2021-02-12       Impact factor: 11.082

6.  Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.

Authors:  Wenting K Tsai; Kirstin A Zettlitz; Richard Tavaré; Naoko Kobayashi; Robert E Reiter; Anna M Wu
Journal:  Theranostics       Date:  2018-11-12       Impact factor: 11.556

7.  Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer.

Authors:  Margret Schottelius; Alexander Wurzer; Katharina Wissmiller; Roswitha Beck; Maximilian Koch; Dimitrios Gorpas; Johannes Notni; Tessa Buckle; Matthias N van Oosterom; Katja Steiger; Vasilis Ntziachristos; Markus Schwaiger; Fijs W B van Leeuwen; Hans-Jürgen Wester
Journal:  J Nucl Med       Date:  2018-09-20       Impact factor: 10.057

8.  Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer.

Authors:  Lior Rosenfeld; Amiram Sananes; Yuval Zur; Shira Cohen; Kalyan Dhara; Sigal Gelkop; Efrat Ben Zeev; Anat Shahar; Leslie Lobel; Barak Akabayov; Eyal Arbely; Niv Papo
Journal:  J Med Chem       Date:  2020-06-08       Impact factor: 7.446

9.  In situ Generated <sup>212</sup>Pb-PSMA Ligand in a <sup>224</sup>Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells.

Authors:  Vilde Y Stenberg; Asta Juzeniene; Øyvind S Bruland; Roy H Larsen
Journal:  Curr Radiopharm       Date:  2020

Review 10.  PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery.

Authors:  Yvonne H W Derks; Dennis W P M Löwik; J P Michiel Sedelaar; Martin Gotthardt; Otto C Boerman; Mark Rijpkema; Susanne Lütje; Sandra Heskamp
Journal:  Theranostics       Date:  2019-09-20       Impact factor: 11.556
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.